Laboratory technique to multiply a DNA sample for study
POPULARITY
Categories
55 episodes with pcr
63 episodes with pcr
26 episodes with pcr
24 episodes with pcr
24 episodes with pcr
18 episodes with pcr
18 episodes with pcr
31 episodes with pcr
16 episodes with pcr
37 episodes with pcr
12 episodes with pcr
49 episodes with pcr
18 episodes with pcr
10 episodes with pcr
9 episodes with pcr
27 episodes with pcr
14 episodes with pcr
8 episodes with pcr
19 episodes with pcr
16 episodes with pcr
9 episodes with pcr
8 episodes with pcr
10 episodes with pcr
8 episodes with pcr
12 episodes with pcr
21 episodes with pcr
12 episodes with pcr
16 episodes with pcr
21 episodes with pcr
15 episodes with pcr
10 episodes with pcr
20 episodes with pcr
20 episodes with pcr
20 episodes with pcr
13 episodes with pcr
14 episodes with pcr
12 episodes with pcr
13 episodes with pcr
10 episodes with pcr
5 episodes with pcr
18 episodes with pcr
8 episodes with pcr
10 episodes with pcr
8 episodes with pcr
6 episodes with pcr
8 episodes with pcr
10 episodes with pcr
10 episodes with pcr
8 episodes with pcr
9 episodes with pcr
4 episodes with pcr
5 episodes with pcr
13 episodes with pcr
20 episodes with pcr
7 episodes with pcr
4 episodes with pcr
8 episodes with pcr
7 episodes with pcr
4 episodes with pcr
8 episodes with pcr
7 episodes with pcr
9 episodes with pcr
10 episodes with pcr
8 episodes with pcr
13 episodes with pcr
6 episodes with pcr
7 episodes with pcr
18 episodes with pcr
5 episodes with pcr
10 episodes with pcr
8 episodes with pcr
13 episodes with pcr
8 episodes with pcr
7 episodes with pcr
12 episodes with pcr
12 episodes with pcr
7 episodes with pcr
4 episodes with pcr
7 episodes with pcr
3 episodes with pcr
12 episodes with pcr
5 episodes with pcr
7 episodes with pcr
7 episodes with pcr
5 episodes with pcr
4 episodes with pcr
11 episodes with pcr
5 episodes with pcr
6 episodes with pcr
3 episodes with pcr
5 episodes with pcr
5 episodes with pcr
7 episodes with pcr
10 episodes with pcr
9 episodes with pcr
5 episodes with pcr
6 episodes with pcr
3 episodes with pcr
6 episodes with pcr
6 episodes with pcr
4 episodes with pcr
6 episodes with pcr
3 episodes with pcr
4 episodes with pcr
5 episodes with pcr
7 episodes with pcr
4 episodes with pcr
6 episodes with pcr
7 episodes with pcr
6 episodes with pcr
6 episodes with pcr
6 episodes with pcr
5 episodes with pcr
4 episodes with pcr
3 episodes with pcr
13 episodes with pcr
5 episodes with pcr
5 episodes with pcr
3 episodes with pcr
9 episodes with pcr
4 episodes with pcr
5 episodes with pcr
3 episodes with pcr
4 episodes with pcr
3 episodes with pcr
7 episodes with pcr
2 episodes with pcr
8 episodes with pcr
6 episodes with pcr
12 episodes with pcr
3 episodes with pcr
5 episodes with pcr
5 episodes with pcr
2 episodes with pcr
13 episodes with pcr
4 episodes with pcr
3 episodes with pcr
4 episodes with pcr
8 episodes with pcr
4 episodes with pcr
5 episodes with pcr
5 episodes with pcr
4 episodes with pcr
2 episodes with pcr
4 episodes with pcr
2 episodes with pcr
3 episodes with pcr
5 episodes with pcr
6 episodes with pcr
4 episodes with pcr
5 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
7 episodes with pcr
7 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
2 episodes with pcr
4 episodes with pcr
9 episodes with pcr
Professor Norman Fenton is a mathematician and risk expert who rose to prominence during COVID for cutting through flawed statistics and exposing how data was used and misused to shape policy. “There was never any justification for the lockdowns in the first place, and the whole COVID hysteria was based on massively exaggerated case and mortality numbers created by flawed definitions, easily manipulated data, and inaccurate mass testing of healthy people.” In this episode, Dr. Brian, Dr. Tro, and Prof. Norman talk about… (00:00) Intro (01:52) Governmental misinterpretation of Covid data and the resulting Covid policies (12:05) False Covid case numbers (17:40) The complicity of the scientific, academic, and physician communities in Covid vaccine policies and lockdown policies (25:12) How flawed and manipulated the PCR test is (29:02) The true devestation of the lockdowns (32:55) Prof. Norman's fellow colleagues who joined him in challenging the Covid narrative (35:29) Early warning signs that the mRNA Covid vaccines were not going to be safe or effective (46:55) How the all-cause mortality data has changed since the initial release of the vaccines (48:30) Vaccine risk/benefit for healthy, fit people (49:47) Early red flags about the whole Covid situation and governmental responses (51:16) How much money people made off of the Covid situation (54:28) Prof. Norman's personal experience fighting the Covid machine (01:01:39) Israel's Covid mortality data and suppression of valid data from respected researchers (01:08:50) Why vaccine related deaths are probably exaggerated For more information, please see the links below. Thank you for listening! Links: Please consider supporting us on Patreon: https://www.lowcarbmd.com/ Prof. Norman Fenton: Website: https://www.normanfenton.com X: https://x.com/profnfenton Fighting Goliath (book): https://wherearethenumbers.substack.com/p/our-book-out-now-fighting-goliath YouTube: https://www.youtube.com/channel/UCygtzcy5WGNluXjhA1cuT9w Dr. Brian Lenzkes: Website: https://arizonametabolichealth.com/ Twitter: https://twitter.com/BrianLenzkes?ref_src=twsrc^google|twcamp^serp|twgr^author Dr. Tro Kalayjian: Website: https://www.doctortro.com/ Twitter: https://twitter.com/DoctorTro IG: https://www.instagram.com/doctortro/ Toward Health App Join a growing community of individuals who are improving their metabolic health; together. Get started at your own pace with a self-guided curriculum developed by Dr. Tro and his care team, community chat, weekly meetings, courses, challenges, message boards and more. Apple: https://apps.apple.com/us/app/doctor-tro/id1588693888 Google: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.doctortro&hl=en_US&gl=US Learn more: https://doctortro.com/community/
Rebecca Culshaw Smith's Substack, “The Real AIDS Epidemic,” highlights core criticisms of mainstream HIV/AIDS theory, medical testing, pharmaceutical practices, and challenges to scientific orthodoxy. Based on her popular posts, interviews, and thematic content, these are 20 of the most important ideas advanced on her platform: 1. Questioning the existence of HIV as a unique virus, arguing that classic virological isolation (Koch's postulates) has not been fulfilled. 2. Highlighting the non-specificity and cross-reactivity of HIV antibody tests, leading to potential misdiagnosis. 3. Criticism of “viral load” PCR tests for not detecting whole pathogens but only RNA fragments. 4. Noting the shifting criteria for HIV test positivity over time, calling diagnostic standards into question. 5. Documenting long-term “non-progressors” and “elite controllers” who remain healthy without antiretroviral therapy. 6. Raising awareness of AIDS-defining illnesses in HIV-negative individuals and questioning causality. 7. Arguing that hazard from AIDS medications (e.g., AZT, Truvada, Prep) may outweigh their benefits, especially due to their toxicity and inconsistent trial results. 8. Critique of the marketing and deployment of pre-exposure prophylaxis (Prep), calling it a pharmaceutical “scandal” targeting people not at significant risk. 9.Exploring how COVID-19 public health narratives mirror what she views as deception and fear tactics from the AIDS era. 10. Disputing the epidemiological narrative that AIDS is globally caused by a single infectious agent, and highlighting massive regional/demographic inconsistencies. 11. Exposing groupthink, censorship, and reputational shaming used against scientists questioning the HIV/AIDS paradigm. 12. Emphasizing failures of antiretroviral therapy in preventing disease progression for many patients. 13.. Explaining the statistical and mathematical problems in foundational HIV/AIDS research and the “shaky foundation” of guiding studies. 14. Arguing that AIDS-defining diseases may often reflect toxicity, malnutrition, or existing comorbidities, not a distinct viral syndrome. 15. Linking historical and social factors (such as drug use, pharmaceutical incentives) to the creation and persistence of the HIV/AIDS establishment. 16. Alerting readers to issues of false positive antenatal screening and broader concerns about mass diagnostic testing in medicine. 17. Suggesting that “virus-like particles” in the body are misidentified as pathogens, not proof of HIV's existence. 18. Forecasting that advances in AI and technology may help overturn scientific “consensus” by increasing transparency and debate. 19 Publicly refuting hit pieces and attempts to “cancel” her work as ideological suppression, not science. 20.Advocating for a return to fundamental scientific rigor and genuine skepticism in medical research, especially around virology and public health narratives. These topics synthesize her core objections to HIV/AIDS orthodoxy and frame her Substack as a point of dissent and critique against modern medical paradigms and their social consequences.
Bartonella is a genus of Gram-negative bacteria. It is the only genus in the family Bartonellaceae. Facultative intracellular parasites, Bartonella species can infect healthy people, but are considered especially important as opportunistic pathogens. Bartonella species are transmitted by vectors such as fleas, sand flies, and mosquitoes. At least eight Bartonella species or subspecies are known to infect humans. Bartonella henselae is the organism responsible for cat scratch disease. History Bartonella species have been infecting humans for thousands of years, as demonstrated by Bartonella quintana DNA in a 4000-year-old tooth. The genus is named for Alberto Leonardo Barton Thompson (1871–October 26, 1950), a Peruvian scientist. Infection cycle Though some studies have found "no definitive evidence of transmission by a tick to a vertebrate host," Bartonella species are well-known to be transmissible to both animals and humans through various other vectors, such as fleas, lice, and sand flies. Bartonella bacteria are associated with cat-scratch disease, but a study in 2010 concluded, "Clinicians should be aware that ... a history of an animal scratch or bite is not necessary for disease transmission." All current Bartonella species identified in canines are human pathogens. SUMMARY Bartonella is a type of bacteria that can make people very sick. There are three main kinds that cause most of the infections: B. henselae, B. quintana, and B. bacilliformis. Some of these bacteria are found all over the world (like B. henselae), but others only live in certain places (like B. bacilliformis). People can catch Bartonella in different ways: B. henselae – usually from a cat scratch or bite. B. quintana – spread by body lice. B. bacilliformis – spread by sand flies. Once the bacteria get into the body, they infect red blood cells and cause the blood vessels to grow abnormally. This can lead to symptoms like long-lasting fever, swollen lymph nodes, and enlarged liver or spleen. Doctors figure out if someone has Bartonella using lab tests. They might grow the bacteria in a culture, look for antibodies in the blood (serology), or look at tissues under a microscope. Special tests called PCR can find Bartonella DNA in blood or tissue samples, including heart valves. Treatment usually involves antibiotics, but the exact medicine depends on which type of Bartonella you have and how sick you are. In some cases, like with cat-scratch disease, a doctor may need to use a needle to drain swollen lymph nodes.
5324 風とあそぶ：） 20250928SUN 今日のCOVID-19・・・1778回目マダニ・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5321 風とあそぶ：） 20250927SAT 今日のCOVID-19・・・1777回目風疹撲滅・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5318 風とあそぶ：） 20250926FRI 今日のCOVID-19・・・1776回目個人公衆衛生学・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5315 風とあそぶ：） 20250925THU 今日のCOVID-19・・・1775回目エボラ出血熱・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5312 風とあそぶ：） 20250924WED 今日のCOVID-19・・・1774回目人災・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5309 風とあそぶ：） 20250923TUE 今日のCOVID-19・・・1773回目空気感染にはマスク!!!・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5306 風とあそぶ：） 20250922MON 今日のCOVID-19・・・1772回目実際と数値の違いに声が上がる・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5303 風とあそぶ：） 20250921SUN 今日のCOVID-19・・・1771回目改めて自分を守る事から・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5300 風とあそぶ：） 20250920SAT 今日のCOVID-19・・・1770回目分断・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
O que antes parecia simples — AINE + colchicina e, na dúvida, corticoide — agora tem um novo protagonista: os anti-IL1.Neste episódio do DozeCast, Mateus Prata, William Batah e o especialista Dr. Vinícius Correia trazem todas as novidades sobre Pericardita e explicam de forma clara e prática:Por que o corticoide deixou de ser primeira escolha na recorrente.Os novos critérios diagnósticos.Quando encaminhar para os Centros de Excelência em Doenças Pericárdicas.E, principalmente: o que você deve mudar amanhã na sua conduta.Minutagem:(03:32) - Epidemiologia da Pericardite Aguda(05:18) - Quem é o paciente mais suscetível a Pericardite Aguda?(06:38) - As principais causas de Pericardite Aguda(10:30) - A importância do novo consenso de Pericardite Aguda(12:18) - Novos critérios diagnósticos de Pericardite Aguda(24:09) - ECO e Ressonância, para quem indicar na Pericardite Aguda?(26:03) - Exames laboratoriais que devem ser solicitados na Pericardite Aguda(28:04) - Quem é o paciente que deve ser internado por Pericardite Aguda?(32:10) - A importância da PCR na Pericardite Aguda(35:16) - Tratamento clínico da Pericardite Aguda(45:15) - Quando devo dar corticoide no tratamento da Pericardite Aguda?(47:40) - Quais pacientes merecem transferência para um centro especializado?(50:40) - Pericardiotomia, quando deve ser indicada?_____________________________Assine agora! Revisões didáticas de Cardiologia, semanalmente na DozeNews PRIME: a maneira mais leve e rápida de se manter atualizado(a), através do link dozeporoito.com/prime
5297 風とあそぶ：） 20250919FRI 今日のCOVID-19・・・1769回目感染症対策・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5294 風とあそぶ：） 20250918THU 今日のCOVID-19・・・1768回目研究は続く・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
Dr. Kathleen Horst, Dr. Rachel Jimenez, and Dr. Yara Abdou discuss the updated guideline from ASTRO, ASCO, and SSO on postmastectomy radiation therapy. They share new and updated recommendations on topics including PMRT after upfront surgery, PMRT after neoadjuvant systemic therapy, dose and fractionation schedules, and delivery techniques. They comment on the importance of a multidisciplinary approach and providing personalized care based on individual patient characteristics. Finally, they review ongoing research that may impact these evidence-based guidelines in the future. Read the full guideline, “Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline” at www.asco.org/breast-cancer-guidelines" TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01747 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Kathleen Horst, expert panel chair from Stanford University; Dr. Rachel Jimenez, expert panel vice chair from Massachusetts General Hospital; and Dr. Yara Abdou, ASCO representative from the University of North Carolina, authors on "Postmastectomy Radiation Therapy: An American Society for Radiation Oncology, American Society of Clinical Oncology, and Society of Surgical Oncology Clinical Practice Guideline." Thank you for being here today, Dr. Horst, Dr. Jimenez, and Dr. Abdou. Dr. Kathleen Horst: Thank you for having us. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Horst, Dr. Jimenez, and Dr. Abdou who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Then to dive into the content that we are here today to talk about, Dr. Horst, could you start us off by describing what prompted the update for this joint guideline between ASTRO, ASCO, and SSO, and what is the scope of this 2025 guideline on postmastectomy radiation therapy? Dr. Kathleen Horst: Thank you. This joint guideline was last updated in 2016. Over the past decade, the treatment of breast cancer has evolved substantially. Newer systemic therapy regimens have increasingly personalized treatment based on tumor biology, and local therapy management has explored both the de-escalation of axillary surgery and more abbreviated courses of radiation therapy. Given these advances, it was important to revisit the role of postmastectomy radiotherapy in this modern era of breast cancer therapy. This updated guideline addresses four key questions, including postmastectomy radiation therapy after upfront surgery as well as after neoadjuvant systemic therapy. It also reviews the evolving role of various dose and fractionation schedules and optimal treatment techniques and dose constraints. Brittany Harvey: Excellent. I appreciate that background, Dr. Horst. So then, next, Dr. Jimenez, I would like to review the recommendations of this guideline across those four key questions that Dr. Horst just mentioned. So first, what does the panel recommend for PMRT for patients who received initial treatment with mastectomy? Dr. Rachel Jimenez: The panel provided pretty strong consensus that patients with positive lymph nodes or patients with large tumors involving the skin or the chest wall should receive postmastectomy radiation. However, the panel also recognized that the omission of postmastectomy radiation may be appropriate for select patients who have positive lymph nodes and have an axillary lymph node dissection if they have a low nodal burden and other favorable clinical or pathologic features. For patients without lymph node involvement at the time of surgery and no involvement of the skin or chest wall, postmastectomy radiation was not advised by the panel. Brittany Harvey: Understood. It is helpful to understand those recommendations for that patient population. Following that, Dr. Abdou, what are the key recommendations for PMRT for patients who received neoadjuvant systemic therapy before mastectomy? Dr. Yara Abdou: When we think about PMRT after neoadjuvant treatment, the key point is that the initial stage of presentation still matters a lot. So for example, if a patient comes in with more advanced disease, say a large primary tumor, like a clinical T4, or more extensive nodal disease, like an N2 or N3 disease, those patients should get PMRT, no matter how well they respond to neoadjuvant therapy, because we know it reduces the risk of recurrence and that has been shown pretty consistently. On the other hand, if there are still positive lymph nodes after neoadjuvant treatment, basically residual nodal disease, PMRT is also strongly recommended because the risk of local-regional recurrence is much higher in that setting. The gray area is the group of patients who start with a lower burden of nodal disease, such as N1 disease, but then become node negative at surgery. For those patients, we tend to individualize the decision. So if the patient is young or has triple-negative disease, or if there is a lot of residual disease in the breast even though the nodes are cleared, then radiation is probably helpful. But if everything has melted away with pCR in both the breast and the nodes, then it may be safe to omit PMRT in those patients. For patients with smaller tumors and no nodal involvement to begin with, like a clinical T1-T2 N0, if they are still node negative after neoadjuvant treatment, then PMRT is generally not recommended because their baseline recurrence risk is low. And finally, if the margins are positive and cannot be re-excised, then PMRT is recommended after neoadjuvant therapy. Brittany Harvey: Yes, those distinctions are important for appropriate patient selection. So then, Dr. Horst, we have just reviewed the indications for PMRT, but for those patients who receive PMRT, what are the appropriate treatment volumes and dose fractionation regimens? Dr. Kathleen Horst: The guideline addresses coverage of the chest wall and regional nodes with a specific discussion of the data regarding internal mammary nodal irradiation, which has been an area of controversy over many years. The guideline also reviews the data exploring moderate hypofractionation, or shorter courses of radiation therapy. The task force recommends utilizing moderate hypofractionation for the majority of women requiring postmastectomy radiation, which is likely to have a large impact on clinical practice. This recommendation is based on the evolving data demonstrating that a 3-week course of radiotherapy after mastectomy provides similar oncologic outcomes and minimal toxicity for most patients compared to the standard 5-week treatment course. Brittany Harvey: Thank you for reviewing that set of recommendations as well. So then, Dr. Jimenez, to wrap us up on the key questions here, what delivery techniques are recommended for treating patients who receive PMRT? Dr. Rachel Jimenez: So this portion of the guideline is likely to be most helpful for radiation oncologists because it represents the most technical part of the guideline, but we do believe that it offers some important guidance that has, to this point, been lacking in the postmastectomy radiation setting. So first, the panel recommends that all patients should undergo 3-dimensional radiation planning using CAT scan based imaging, and this includes contouring. So contouring refers to the explicit identification, using a drawing interface on the CAT scan imaging, by the radiation oncologist to identify the areas that are targeted to receive radiation, as well as all of the nearby normal tissues that could receive unintended radiation exposure. And we also provide radiation oncologists in the guideline with suggestions about how much dose each target tissue should receive and what the dose limits should be for normal tissues. Additionally, we make some recommendations regarding the manner in which radiation is delivered. So for example, we advise that when conventional radiation methods are not sufficient for covering the areas of the body that are still at risk for cancer, or where too high of a dose of radiation would be anticipated to a normal part of the body, that providers employ a technique called intensity modulated radiation therapy, or IMRT. And if IMRT is going to be used, we also advise regular 3-dimensional imaging assessments of the patient's body relative to the treatment machine to ensure treatment fidelity. When the treatments are delivered, we further advise using a deep inspiration breath-hold technique, which lowers the exposure to the heart and to the lungs when there is concern for cardiopulmonary radiation exposure, and again, that image guidance be used along with real-time monitoring of the patient's anatomy when those techniques are employed. And then finally, we advise that patients receiving postmastectomy radiation utilize a bolus, or a synthetic substance placed on the patient's skin to enhance radiation dose to the superficial tissue, only when there is involvement of the skin with cancer or other high-risk features of the cancer, but not for every patient who receives postmastectomy radiation. Brittany Harvey: Understood. And then, yes, you just mentioned that section of the guideline is probably most helpful for radiation oncologists, but I think you can all comment on this next question. What should all clinicians, including radiation oncologists, surgical oncologists, medical oncologists, and other oncologic professionals, know as they implement all of these updated recommendations? Dr. Rachel Jimenez: So I think one of the things that is most important when we consider postmastectomy radiation and making recommendations is that this is a multidisciplinary panel and that we would expect and encourage our colleagues, as they interpret the guidelines, to employ a multidisciplinary approach when they are discussing each individual patient with their surgical and medical oncology colleagues, that there is no one size fits all. So these guidelines are intended to provide some general guidance around the most appropriate techniques and approaches and recommendations for the utilization of postmastectomy radiation, but that we recognize that all of these recommendations should be individualized for patients and also represent somewhat of a moving target as additional studies, both in the surgical and radiation oncology realm as well as in the systemic therapy realm, enter our milieu, we have to adjust those recommendations accordingly. Dr. Kathleen Horst: Yeah, I would agree, and I wanted to comment as a radiation oncologist, we recognize that local-regional considerations are intertwined with systemic therapy considerations. So as the data evolve, it is critical to have these ongoing updates in a cross-disciplinary manner to ensure optimal care for our patients. And as Dr. Jimenez mentioned, these multidisciplinary discussions are critical for all of us to continue to learn and understand the evolving recommendations across disciplines but also to individualize them according to individual patients. Dr. Yara Abdou: I could not agree more. I think from a medical oncology perspective, systemic therapy has gotten much better with adjuvant CDK4/6 inhibitors, T-DM1, capecitabine, and immune therapy. So these are all newer adjuvant therapies, so the baseline recurrence risks are lower than what they were in the trials that established PMRT. So the absolute benefit of radiation varies more now, so smaller for favorable biology but still relevant in aggressive subtypes or with residual disease. So it is definitely not a one-size-fits-all. Brittany Harvey: Yes, I think it is important that you have all highlighted that multidisciplinary approach and having individualized, patient-centric care. So then, expanding on that just a little bit, Dr. Abdou, how will these guideline recommendations affect patients with breast cancer? Dr. Yara Abdou: So basically, reiterating what we just talked about, these guidelines really move us towards personalized care. So for patients at higher risk, so those with larger tumors, multiple positive nodes, or residual nodal disease after neoadjuvant therapy, PMRT remains essential, consistently lowering local-regional recurrence and improving survival. But for patients at intermediate or lower risk, the recommendations support a more selective approach. So instead of a blanket rule, we now integrate tumor biology, response to systemic therapy, and individual patient factors to decide when PMRT adds meaningful benefit. So the impact for patients is really important because those at high risk continue to get the survival advantage of radiation while others can be spared the unnecessary treatment and side effects. So in short, we are aligning PMRT with modern systemic therapy and biology, making sure each patient receives the right treatment for their situation. Brittany Harvey: Absolutely. Individualizing treatment to every patient will make sure that everyone can achieve the best outcomes as possible. So then, Dr. Jimenez, to wrap us up, I believe Dr. Horst mentioned earlier that data continues to evolve in this field. So in your opinion, what are the outstanding questions regarding the use of PMRT and what are you looking to for the future of research in this space? Dr. Rachel Jimenez: So there are a number of randomized phase III clinical trials that are either in active accrual or that have reported but not yet published that are exploring further de-escalation of postmastectomy radiation and of axillary surgery. And so we do not yet have sufficient data to understand how those two pieces of information integrate with each other. So for example, if you have a patient who has a positive lymph node at the time of diagnosis and forgoes axillary surgery aside from a sentinel lymph node biopsy, we do not yet know that we can also safely forgo radiation entirely in that setting. So we expect that future studies are going to address these questions and understand when it is appropriate to simultaneously de-escalate surgery and radiation. Additionally, there is a number of trials that are looking at ways in which radiation could be omitted or shortened. So there is the RT CHARM trial, which has reported but not yet published, looking at a shorter course of radiation. And so we do make recommendations around that shorter course of radiation in this guideline, but we anticipate that the additional data from the RT CHARM study will provide further evidence in support of that. Additionally, there is a study called the TAILOR RT trial, which looks at forgoing postmastectomy radiation in patients who, to Dr. Abdou's point, have a favorable tumor biology and a low 21-gene recurrence score. And so we are going to anticipate the results from that study to help guide who can selectively forgo postmastectomy radiation when they fall into that favorable risk category. So there are a number of questions that I think will help flesh out this guideline. And as they publish, we will likely publish a focused update on that information to help provide context for our colleagues in the field and clarify some of these recommendations to suit the latest data. Brittany Harvey: Absolutely. We will look forward to those de-escalation trials and ongoing research in the field to build on the evidence and look for future updates to this guideline. So I want to thank you for your work to update these guidelines, and thank you for your time today, Dr. Horst, Dr. Jimenez, and Dr. Abdou. Dr. Rachel Jimenez: Thank you. Dr. Yara Abdou: Thank you. Dr. Kathleen Horst: Thank you. Brittany Harvey: And then finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
5291 風とあそぶ：） 20250917WED 今日のCOVID-19・・・1767回目教育の場での感染拡大・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5288 風とあそぶ：） 20250916TUE 今日のCOVID-19・・・1766回目予防を検査を・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5285 風とあそぶ：） 20250915MON 今日のCOVID-19・・・1765回目対策の日常化・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5282 風とあそぶ：） 20250914SUN 今日のCOVID-19・・・1764回目高温と症状と通院と・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
In this episode of Speaking of Mol Bio, host Steve Lewis speaks with Dr. Melissa Wu, co-founder and CEO of Seeding Labs, a nonprofit that's redefining global scientific access. Dr. Wu shares the inspiring story of how Seeding Labs helps institutions in developing nations build research infrastructure by redistributing surplus laboratory equipment from partners like Thermo Fisher Scientific.With an innovative model that connects equipment donors in the global North with universities and institutes across Africa, Asia, and Latin America, Seeding Labs enables groundbreaking science in places where opportunity is limited but talent is abundant. Dr. Wu highlights examples like the Malawi University of Science and Technology, whose graduates are now staffing the country's first hospital microbiology labs, and a Beninese research team using donated PCR equipment to improve the yield of indigenous crops like the miracle berry.More than a logistics operation, Seeding Labs is also fostering scientific networks, reversing brain drain, and giving researchers confidence, courage, and agency. Dr. Wu offers a compelling vision of an equitable global scientific ecosystem, and shares how listeners can get involved—whether by donating equipment, funds, or simply spreading the word. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague. Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.
Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Josh Sigurdson reports on the news of Covid Masks returning in western California as the CDC claims the west coast is at "high" of "very high" levels of so-called "Covid." This news comes as the UK plans the largest pandemic exercise in history (Exercise Pegasus) and Trump meets with Bill Gates. As we move into the autumn, this propaganda will only become louder. This year, the medical establishment and media are working overtime to fear monger about new pandemics, from the Bubonic Plague to Bird Flu, West Nile, Dengue, Chikungungya, Measles, Monkeypox and of course the infamous "SARS-CoV2." As per usual, there are no isolates, there is wastewater data which is heavily utilizing PCR tests which we already know are fraudulent when it comes to direct diagnosis. RFK Jr just sat through another hearing and insisted the covid injections will remain available for everyone. So far the only "justice" we've seen is a warning label for some. Meanwhile, 4 new mRNA Vaccines have been approved for children 6 months to 11 years old. While just 2 weeks ago, President Trump claimed he didn't get enough credit for Operation Warp Speed which disabled 36 million Americans and claimed that it was one of the greatest achievements in American history, claiming it was a "military procedure," he claimed just days later that he may have been mislead about the Vaccines. Wow... 5 and a half years later he thinks he may have been mislead. The fact that people are actually excited about this statement says a lot. How completely asleep does someone have to be to only slightly question the vaccines 5 and a half years later? This isn't an accomplishment, it's embarassing. Besides, he's demanding big pharma show proof of the vaccines' success, not failures. Don't get too hung up on this thinking this will be the end of big pharma. Emergency orders planned for the future "pandemics" are readily in place regardless of the president, but it's clear that Trump is either years behind and stupid OR an evil fraud pretending to start to question this NOW. That is for you to decide. Stay tuned for more from WAM! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# EVERYTHING SOLD OUT EXCEPT... Freeze dried chicken! 50% off with code WAM50! https://wambeef.com/ GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5% plus free shipping! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2025
Lending his 25-year-old OLD soul voice, Canadian Liev Dalton, creator and host of his podcast and collective Beyond Terrain, shares his truth awakening story from his time in college. He observed firsthand the flaws of academia and science, from germ theory to PCR tests, and used the lockdown period to study, reflect and think critically. In our episode, he discusses the nature of law, fires, glyphosate spraying, whole terrain, synthetics, toxins and talks of dentistry by highlighting the studies of Canadian dentist, Westin A. Price. PS - he now has a master's in counseling psychology and runs a wilderness therapy practice. Closing with the "Just Be Practice," he encourages us to look outward so we can turn inward.Show Reference:Westin A. Price: https://www.westonaprice.org/#gsc.tab=0Connect with Liev:Website: https://BeyondTerrain.com/beyond-terrain-academy IG: https://www.instagram.com/beyond.terrain/?hl=en*Host Eden Koz is a soul realignment specialist utilizing psychological empathy, intuition, psychic ability, mediumship, meditation, mindset shift, Reiki, dimensional and galactic healing, to name a few. She also performs spiritual Co#id Vac+ Healing as well as remote & face-to-face sessions with individuals and groups. Contact info for Eden Koz / Just Be®, LLC:Website: EdenJustBe.com Socials: Insta, FB, FB (Just Be), TikTok, LinkedInJust Be~Spiritual BOOM Podcast can be found on Video directories: BitChute, Rumble, YouTube, Odysee, Grassroots Warrior Network. Audio directories: Apple Podcasts, Spotify, ...
Edwin Gonzalez shares his journey from a BioBuilder apprentice to becoming a lead scientific support specialist at Thermo Fisher by age 23, highlighting how hands-on experiences and mentorship shaped his career path.• Middle school science teacher sparked Edwin's interest in science through engaging projects and supportive environment• First in his family to pursue science, without STEM role models at home• Joined BioBuilder apprenticeship program in 2019 after learning about it from a classmate• Gained first hands-on lab experience learning aseptic technique, pipetting, PCR, and bacterial transformation• Worked on biodesign project to create a device detecting airborne allergens• BioBuilder experience helped him decide to major in biology at Suffolk University• Skills learned at BioBuilder created foundation that made college coursework easier• Landed first industry position at Novo Nordisk through connections from a LabCentral internship• Currently works at Thermo Fisher as a lead scientific support specialist• Role combines lab operations, facilities management and direct research support• Recommends exploring multiple aspects of biology to build a diverse toolkit of experiencesLearn more about BioBuilder's programs for students, educators, and industry professionals here
ResourcesClick here to learn about United Ostomy Associates of America (UOAA) National Quality Ostomy Care Campaign, including the Ostomy and Continent Diversion Patient Bill of Rights,.Click here to view a list of patient resources that the WOCN Society has curated, including services, products, and publications. You can also bookmark and/or share the following web address with your colleagues and patients: IDeserveaWOCNurse.com.Click here to view and use the Peristomal Skin Assessment Guide for Clinicians and Consumers,. You can also bookmark and/or share the following web address with your colleagues and patients: psag.wocn.org.Click here to learn more about Janet's session at WOCNext® 2025, “I Have an Ostomy, Where can I go?: Challenges of Setting Up An Ostomy Clinic,.”The WOCN Society, in collaboration with the American Society of Colon and Rectal Surgeons (ASCRS) and the American Urological Association (AUA), developed the educational resources to assist clinicians in selecting an effective stoma site. Click here to review these resources.If you're a healthcare professional looking to deepen your knowledge of ostomy care, explore the joint WOCN and ASCRS Ostomy Care Management (OCM) Program—an evidence-based, online education designed to enhance care delivery and improve outcomes for individuals living with an ostomy. Click here to learn more.Journal of Wound, Ostomy, and Continence Nursing (JWOCN®) articles referenced in this episode:Bridging the Gap: Perceived Educational Needs in the Inpatient to Home Care Setting for the Person With a New OstomyLessons Learned About Peristomal Skin Complications Secondary Analysis of the ADVOCATE TrialOstomy and Continent Diversion Patient Bill of Rights Research Validation of Standards of CareOther articles referenced in this episode: The ostomy leak impact tool: development and validation of a new patient-reported tool to measure the burden of leakage in ostomy device usersImpact of stoma leakage in everyday life: data from the Ostomy Life Study 2019Factors impairing quality of life for people with an ostomy About the SpeakerJanet has enjoyed 40 years in WOC Nursing. Although her early nursing career focus was critical care as a certified critical care registered nurse she certified as a CWOCN in 1985. In 1996, she embarked in a private WOC practice, first as a partnership and then as sole proprietor practicing across the continuum with a focus on ostomy care coupled with a passion for patients attaining their desirable quality of life. Janet worked in outpatient ostomy clinics serving different populations and challenges... adding a bit of spice to her practice and recently retired from patient care.Janet lectures nationally and internationally, has published on Quality of Life of People Living with an Ostomy and co-authored both a home study course on Wound Management & Healing and an educational video on Common Perineal Skin Injuries, and. She participates in Ostomy and Incontinence Associated Dermatitis research and actively participates with WOCN and industry to move ostomy care forward. Her peers awarded her the PCR* ET Nurse of the Year Award in 1996, PCR* President's Award in 2000 and PCR* Professional Educational Award in 2004.*PCR stands for the Pacific Coast Region of the WOCN Society, what is now known as the Pacific Coast Chapter of the WOCN Society (or PCC for short). The WOCN Society has 11 chapters throughout the country that support WOCN members at a local level with resources, education, networking opportunities, social gatherings, timely information, and more. For additional information, please visit wocn.org/Chapters. Editing and post-production work for this episode was provided by The Podcast Consultant.
Can you handle the heat? Aarati tells the story of the nature-loving scientist whose discovery of Thermus aquaticus, a microbe living in the hot waters of Yellowstone Park, helped make PCR one of the fundamental tools of biotech. Support the showFor more information and sources for this episode, visit https://www.smartteapodcast.com.
YEP…Its another episode of You Asked, We Answered! In this episode, we will look at the data to answer 2 questions that came into the show within the last 24 hrs: 1. Is oral or topical therapy best for first treatment of uncomplicated vulvovaginal candidiasis? (We have new data- AJOG, Sept 2025, to answer that), and 2. Is urine PCR testing for UTI diagnosis a “routine practice”? (We will look at 4 sources of information to answer that one). Listen in for details. 1. Gardella, Barbara et al. Treatment of uncomplicated vulvovaginal candidiasis: topical or oral drugs? Single-day or multiple-day therapy? A network meta-analysis of randomized trials. American Journal of Obstetrics & Gynecology, Volume 233, Issue 3, 152 - 1612. Invited Commentary: JAMA Netw Open: Published Online: November 26, 20242024;7;(11):e2446711. doi:10.1001/jamanetworkopen.2024.467113. March 2025 (AAFP): Are the Advantages of Urine PCR Testing Worth the Higher Costs? https://www.aafp.org/pubs/afp/afp-community-blog/entry/are-the-advantages-of-urine-pcr-testing-worth-the-higher-costs.html4. July 2025: PALTmed: https://paltmed.org/news-media/paltmed-calls-providers-stop-using-routine-pcr-urine-tests-utis5. https://pathnostics.com/limitations-of-pcr-only/
Drs. Whitney Hartlage (@whithartlage11) and Sam Windham join Dr. Ryan Moenster to discuss updates in the diagnosis and management of community-acquire pneumonia. Hear from our guests on the role of rapid diagnostic tests such as multiplex PCR and urinary antigen tests in the inpatient and outpatient setting, considerations for initiating steroids and withholding macrolides, and when to use short antibiotic durations. Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/. Visit our website! https://breakpoints-sidp.org/ References: Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST. PMID: 31573350; PMCID: PMC6812437. Chaudhuri D, Nei AM, Rochwerg B, Balk RA, Asehnoune K, Cadena R, Carcillo JA, Correa R, Drover K, Esper AM, Gershengorn HB, Hammond NE, Jayaprakash N, Menon K, Nazer L, Pitre T, Qasim ZA, Russell JA, Santos AP, Sarwal A, Spencer-Segal J, Tilouche N, Annane D, Pastores SM. 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia. Crit Care Med. 2024 May 1;52(5):e219-e233. doi: 10.1097/CCM.0000000000006172. Epub 2024 Jan 19. PMID: 38240492. Odeyemi Y, Tekin A, Schanz C, Schreier D, Cole K, Gajic O, Barreto E. Comparative effectiveness of azithromycin versus doxycycline in hospitalized patients with community acquired pneumonia treated with beta-lactams: A multicenter matched cohort study. Clin Infect Dis. 2025 May 16:ciaf252. doi: 10.1093/cid/ciaf252. Epub ahead of print. PMID: 40378193. Butler AM, Nickel KB, Olsen MA, Sahrmann JM, Colvin R, Neuner E, O'Neil CA, Fraser VJ, Durkin MJ. Comparative safety of different antibiotic regimens for the treatment of outpatient community-acquired pneumonia among otherwise healthy adults. Clin Infect Dis. 2024 Oct 23:ciae519. doi: 10.1093/cid/ciae519. Epub ahead of print. PMID: 39442057; PMCID: PMC12355227. Furukawa Y, Luo Y, Funada S, Onishi A, Ostinelli E, Hamza T, Furukawa TA, Kataoka Y. Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis. BMJ Open. 2023 Mar 22;13(3):e061023. doi: 10.1136/bmjopen-2022-061023. PMID: 36948555; PMCID: PMC10040075 Schober T, Wong K, DeLisle G, et al. Clinical outcomes of rapid respiratory virus testing in emergency departments. JAMA Intern Med. 2024;184(5):528-536. Clark T, Lindsley K, Wigmosta T, et al. Rapid multiplex PCR for respiratory viruses reduces time to result and improves clinical care: results of a systematic review and meta-analysis. J Infect. 2023;86(5):462-475. May L, Robbins EM, Canchola JA, Chugh K, Tran NK. A study to assess the impact of the cobas point-of-care RT-PCR assay (SARS-CoV-2 and Influenza A/B) on patient clinical management in the emergency department of the University of California at David Medical Center. J Clin Virol. 2023:168:105597. Cartuliares MB, Rosenvinge FS, Mogensen CB, Skovsted TA, Andersen SL, Østergaard C, et al. Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: a multicentre randomised controlled trial. PLoS Med. 2023;20:e1004314. doi: 10.1371/ journal.pmed.1004314. Vaughn VM, Dickson RP, Horowitz JK, Flanders SA. Community-acquired pneumonia: a review. JAMA. 2024;332(15):1282-1295. Davis MR, McCreary EK, Trzebucki AM. Things we do for no reason – ordering Streptococcus pneumoniae urinary antigen in patients with community-acquired pneumonia. Open Forum Infect Dis. 2024;11(3):ofae089. Centers for Disease Control and Prevention. Laboratory Testing for Legionella. Updated June 9, 2025. Accessed July 13, 2025. https://www.cdc.gov/legionella/php/laboratories/index.html. Jain S, Self WH, Wunderink RG. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427. Kamat IS, Ramachandram V, Eswaran H, Guffey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(3):538-542. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single blinded intervention trial. Lancet. 2004;363:600–7. doi: 10.1016/S0140- 6736(04)15591-8. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302:1059–66. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalci- € tonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Datab System Rev. 2017;10(10):CD007498. doi: 10.1002/14651858. cd007498.pub2. Huang DT, Yealy DM, Filbin MR, Brown AM, Chang C-CH, Doi Y, et al. Procalcitonin-guided use of antibiotics for lower Respiratory tract infection. New Engl J Med. 2018;379:236–49. doi: 10.1056/NEJMoa1802670. Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;389(19):1623-1634. doi:10.1056/NEJMoa2215145. Gupta AB, Flanders SA, Petty LA, et al. Inappropriate diagnosis of pneumonia among hospitalized adults. JAMA Intern Med. 2024;184(5):548-556. Jones BE, Chapman AB, Ying J, et al. Diagnostic Discordance, Uncertainty, and Treatment Ambiguity in Community-Acquired Pneumonia: A National Cohort Study of 115 U.S. Veterans Affairs Hospitals. Ann Intern Med. 2024;177(9):1179-1189. doi:10.7326/M23-2505. Hartlage W, Imlay H, Spivak ES. The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia. Antimicrob Steward Healthc Epidemiol. 2024;4(1):e214. doi:10.1017/ash.2024.453. Dinh A, Barbier F, Bedos JP, et al. Update of guidelines for management of community acquired pneumonia in adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF). Endorsed by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF); endorsed by the French Intensive Care Society (SRLF), the French Microbiology Society (SFM), the French Radiology Society (SFR), and the French Emergency Society (SFMU). Respir Med and Res. 2025. El Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332(7554):1355. doi:10.1136/bmj.332.7554.1355. Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia: a randomized, non-inferiority trial. Lancet. 2021;397(10280):1195-1203.
Dr. Sumanta (Monty) Pal and Dr. Arielle Elkrief discuss the clinical relevance of the gut microbiome in cancer immunotherapy and the importance of antibiotic stewardship, as well as interventions currently being explored to treat gut dysbiosis and optimize immunotherapy response. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hi everyone, I'm Dr. Monty Pal, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist. I'm a professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today we're here to discuss one of my favorite topics, which is the gut microbiome. It's almost hard to avoid the gut microbiome nowadays if you look at medical literature within oncology. It's an emerging phenomenon, but there are a couple of individuals that I would really define as pioneers in the field. And one of them is actually with me today, Dr. Arielle Elkrief, to discuss the clinical relevance of the gut microbiome, particularly amongst patients receiving immunotherapy, although I imagine our conversation today will take many twists and turns. Arielle is an assistant professor and clinician scientist in the Department of Oncology at the University of Montreal, and she is co-director of the CHUM Microbiome Center there. FYI for the listeners, we have our full disclosures in the transcript of this episode. Arielle, thank you so much for joining us today. Dr. Arielle Elkrief: Thanks so much, Monty. This is going to be amazing. Dr. Sumanta (Monty) Pal: Well, I have to tell you what sort of inspired me to bring you on as a guest. It was one of many things, but it was this really terrific ASCO Educational [Book] article that you wrote. Now, I have to tell you, I've read all the articles sort of cover to cover in the book, and they're always a wonderful primer, so if our audience is studying for board research or something of that sort, it's a terrific resource to go through. I have to tell you, this piece on the gut microbiome that you wrote is nothing short of a masterpiece. If you read this cover to cover, it's actually going to give you, I think, a sense of the current state and future state of the field. I wanted to start by just sort of beginning with sort of the origin story for a lot of this, which is this association between the gut microbiome and immunotherapy response. This takes us back several years to this pivotal series of papers in Science. Maybe you could walk our audience through that. Dr. Arielle Elkrief: Absolutely. Well, thank you so much for your kind words about the ASCO [Educational] Book. It was a team effort with a lot of key opinion leaders in the field, so I'm really glad to learn that you've liked it. Moving backwards in terms of how we came to understand that the gut microbiome is essential to priming a response to cancer immunotherapy actually goes back to 2015 and seminal papers that looked at what happens when we take mice that are germ-free mice that have never been exposed to a microbiome. These are mice that are born by cesarean section and essentially live in a bubble. And when we give those mice tumors and treat them, in the first papers with anti-CTLA-4 treatment, we realized that these antibodies don't work at all. And that was the first observation that the presence of a gut microbiome was essential to mounting an anti-cancer immune response. When we supplemented those same mice with beneficial bacteria or feces from responder patients, we were able to restore the response to immunotherapy. And so those were really the first preclinical observations that made us understand the critical role of the microbiome in immunotherapy response. Moving a little bit in the future, we examined the fecal microbiome composition using shotgun metagenomic sequencing in different cohorts of patients with solid tumors, namely lung cancers, kidney cancers, and also skin tumors like melanoma, and found that patients who responded to immunotherapy had a distinct microbiome that was characterized by beneficial bacteria compared to patients who experienced resistance to immunotherapy that had a dysbiotic or diseased microbiome. Dr. Sumanta (Monty) Pal: So, you know, it's interesting, these techniques that we're using to sequence the gut, they're a little bit different. So I wonder if you can give the audience a quick primer on these techniques that you're so well versed in, shotgun metagenomic sequencing, 16S rRNA sequencing. If you had to describe this in 30 seconds, which is a tall task, how would you do that? Dr. Arielle Elkrief: That's a tall task. Much of what we know about the microbiome initially came from a technique called 16S rRNA sequencing. This is a technique that amplifies the 16S region and basically tells you at the genus level what's going on at the level of bacterial composition. This technique is fast, relatively cheap, and can be performed on a laptop computer, which is excellent. The problem is that it's prone to a lot of technical variations. Different primers might give you different results, and you're really limited at the genus resolution. You can't get a good resolution in terms of species, and we're learning that different species from the same genus might have different physiological properties, and the same thing goes at the strain level. So when we really zone in and look at inter-species changes, we're seeing that these actually have specific functions in the host. So that brings us to metagenomic sequencing, which is a whole genome sequencing, next-generation sequencing based method that looks at the whole composition and gives you information not only on bacteria, but you might also get fungal and viral properties. You can zoom in on the strain level. You can also get functional output, so we can examine what the metabolic properties of specific species or strains might look like. The negative aspects of shotgun metagenomic sequencing is that it takes a lot of computational power in order to analyze the results and it might take a little bit longer. And certainly, within the clinical setting, not something that's feasible yet. And that brings us to more novel point-of-care biomarker tools that we've collaborated in developing along with Dr. Laurence Zitvogel and Dr. Lisa Derosa at Gustave Roussy, that learning from the shotgun metagenomics results designed a probe using quantitative PCR which looks for this specific bacteria we know to be important and developed a ratio of harmful bacteria to beneficial bacteria. This is called the TOPOSCORE, and it actually is able to predict quite nicely the response to immunotherapy using a stool sample and a really good turnaround time of almost 72 hours. Dr. Sumanta (Monty) Pal: That was a perfect overview and a lot of information in a short amount of time. It also makes you take out your high school biology textbooks, doesn't it, to understand that the bacterial ribosome, right, is a different size and shape, and that's what we're sequencing here. But these techniques I think are incredibly important, and I'm glad you actually discussed this, this RT-PCR based strategy of calculating the TOPOSCORE. It lends itself to this phenomenon of dysbiosis, and I think for our audience, that's going to be an important term to understand as time goes on. There's the normal healthy gut and then there's this phenomenon of dysbiosis, which is, I guess, simply put, an unhealthy gut. But tell us about, you know, how often you see dysbiosis in a cancer patient, maybe versus a normal healthy adult. Dr. Arielle Elkrief: So, I think we can split up your question into two parts. One is we know from cohort studies and population level-based studies that the microbiome of patients with cancer is distinct from healthy patients or healthy people. And we know that because of the global composition. We also think that there are diversity metrics that lend themselves to being described as dysbiotic. But we do know that the microbiome of people with cancer is distinct from healthy volunteers. That's the first point. In terms of how frequently dysbiosis occurs in patients with cancer, it's not very well defined. We know that even among healthy people, there is a certain level of dysbiosis. Laurence in her talk mentioned that to be about 10% to 20%. And the other fascinating component is that when we're thinking about dysbiosis and the cancer associated microbiome, in terms of the species that are enriched, it's quite striking that a lot of these dysbiotic or negative bacteria are also found to be enriched in patients with metabolic disease, like cardiovascular disease, for example. And so it's unclear if dysbiosis is the cause or consequence, but there definitely seems to be a general pattern of disease when looking at the microbiome compared to healthy people. Dr. Sumanta (Monty) Pal: That's interesting. So, I'll tell you, my second favorite portion of your article, and I'll tell you my favorite portion as well in the context of this podcast, but my second favorite part was the section around antibiotic stewardship. You know, the utilization of antibiotics in a very pragmatic fashion amongst our patients. Can you describe why that's so critical in the context of the microbiome? Dr. Arielle Elkrief: Antibiotics can disrupt the gut microbiome composition. We know this from mouse studies, but also cohort studies of patients that are exposed to antibiotics. And most importantly, we know that patients who are exposed to antibiotics, either before or during the immunotherapy period, have significantly worse progression-free survival and overall survival to immunotherapy. And this is true for immunotherapy in the monotherapy setting, but also when combined with chemotherapy. What's striking is that when we look at patients who are just treated with chemotherapy, we don't see the negative outcome of antibiotics on outcome and progression-free survival and overall survival, suggesting that the negative impact of antibiotics on outcomes is really specific to immunotherapy backbones. The other important point is that this negative signal is maintained even after adjusting for standard prognostic variables in the specific malignancies that we're looking at. And then most importantly, at the mechanistic level, we were able to actually pinpoint the mechanism behind this antibiotic related dysbiosis. And we see this with a bloom of negative bacteria which induces a loss of MAd-CAM, which is an endothelial gut checkpoint immune marker, and that causes an efflux of immunosuppressive T cells, which are usually in the gut, to go straight into the tumor where they make the tumor unamenable to an immunotherapy response. And so now we finally have the mechanism as to why antibiotics are harmful and why we need to practice antibiotic stewardship. Dr. Sumanta (Monty) Pal: And just to be clear for the audience, I mean, if a patient needs antibiotics, they need antibiotics. But perhaps it just suggests that, and we have, I suppose, this predilection as oncologists, just for the minor cold or cough or what have you, we maybe should be a little bit more cognizant of whether or not antibiotics are truly necessary. Is that fair? Dr. Arielle Elkrief: Absolutely. So what we're advocating for is antibiotic stewardship, and this is the clear recommendation that we can make. So that means confirming a bacterial infection. If it's there and antibiotics are indicated, to choose the most narrow spectrum for the shortest course and constantly re-evaluate the indication of antibiotics. And of course, we need to work with our colleagues in infectious diseases who've done incredible work in antibiotic stewardship. And all along this process we also need to be mindful of other medications and polypharmacy, such as proton pump inhibitors or narcotics, for example, we think that these other medications which are frequently prescribed in our cancer population can also potentially have negative impacts on the microbiome and immunotherapy response. Dr. Sumanta (Monty) Pal: I think that's a terrific summary and big guidance for the audience. I promised you I'd tell you my favorite part of your article, and this is this huge table. I think the table is two and a half pages long, if I remember correctly, but it's an awesome table, and I highly recommend our audience to check this out. It lists literally every therapeutic trial for the microbiome under the sun. And so it begins with the approach of fecal microbiota transplant, which I'm going to ask you to tell us about in a second, but it also hinges on a lot of really cool sort of novel therapies, live bacterial products, mixes of different microbial products. Maybe take us through this whole approach of FMT (fecal microbiota transplantation). I actually wasn't aware of the dozens of trials that you listed there in this space. It seems like it's a very active area of research. Dr. Arielle Elkrief: Definitely. So, as you alluded to, FMT or fecal microbiota transplantation is the most well studied and direct way to modify the patient's microbiome. This technique aims to replace the patient's dysbiotic microbiome with that of a healthy microbiome, either from a healthy donor volunteer that's been heavily screened, or from a patient who experienced response to immunotherapy. And, as three landmark studies so far that have been published demonstrated the potential of FMT to reduce primary resistance or secondary resistance to immunotherapy, and this has been in melanoma. We also recently reported on the results of our FMT-LUMINate trial, which looked at patients with lung cancer and melanoma. Once again, FMT, when combined with immunotherapy was safe and led to a higher proportion of responses than we would normally expect. We're now also looking at randomized trials that have come out. So the first being the TACITO trial in kidney cancer, which compared FMT plus pembrolizumab and axitinib to placebo in patients with RCC, and again, FMT was safe and feasible and also led to an increased progression-free survival at one year, meeting the study's primary endpoint. And so, so far, there's a wealth of data really showing the promise of FMT when combined with immunotherapy, and we're now in the process of conducting larger randomized trials, including in melanoma with the CCTG (Canada Cancer Trials Group) in our ME17 or Canbiome2 trial, where we're going to be enrolling 128 patients with metastatic melanoma to receive FMT and standard of care immunotherapy compared to standard of care immunotherapy alone. Dr. Sumanta (Monty) Pal: You're very humble, so I've got to highlight for our audience. This was a mega grant that Arielle received to fund really the largest prospective exploration of FMT that will exist to date. So I'm really excited about that. I wish this was something we could participate in stateside. Before we jump into the other approach, which is live bacterial products and mixes thereof, where do you see FMT going? I think that one of the perceived challenges with FMT is that it's hard to implement, right? You need to have a really robust framework when it comes to gastroenterology, the preparation's challenging. Is there a way to envision FMT use being more generalized? Dr. Arielle Elkrief: Those are great questions. So we're lucky in Canada to work with pioneers in FMT, Michael Silverman, Saman Maleki, and John Lenehan in London, Ontario, who had this really robust FMT healthy donor screening program, which literally screens for every pathogen under the sun, and we haven't had any problems with feasibility or implementing FMT in Canada. But I think that once we're going to hopefully start doing larger scale, randomized phase three studies, that we might run into problems with scalability. And I think also with regards to reproducibility, and that's the feedback that we're getting from some regulatory authorities, especially at the level of the FDA, where there are some concerns around inter- and intra-donor variability because, of course, we can't guarantee that every fecal sample is going to be the same. So that has really pushed the field to think about other strategies, such as live biotherapeutic products which take modified FMT or bacteria from stools from either healthy donors or from responder patients and basically turn them into drugs that are regulated as drugs and can then be studied in the context of investigational new drugs or products. Dr. Sumanta (Monty) Pal: I like this and, you know, I do think that there's a future for it. We just have to kind of put our heads together and figure out how to get over all of these logistical hurdles, but, you know, I agree, I think your group and others have demonstrated, especially with this trial that you're fanning out all throughout Canada, that it can potentially be done. This is a topic that could probably go on for another couple of hours, right, especially based on the size of the table that you put together in this brilliant article, but tell us about live bacterial products or LBPs, as we call them these days. What's the current status, what's the future there? And maybe I'll give you less than two minutes here, although again, I realize it's a two-hour topic. Dr. Arielle Elkrief: You're probably better suited to speak about that because you've been one of the pioneers in terms of this. So we can think about LBPs in terms of single strain organisms, like CBM588 for an example, which your group did some amazing work in showing that, in a randomized setting, that this led to better responses than we would expect compared to just work with controls. We also know that LBPs can have multiple strains, up to 30. We're collaborating with a company called Cannabis Bioscience that is actually working on much larger communities of consortia. And so we're really excited about the direction that that's taking in terms of taking these LBPs and developing them from the drug perspective. In addition to LBPs, we know that there are other ways that we can change the microbiome, notably prebiotics, which are compounds which can have a beneficial impact on the microbiome. And one of these is camu camu, which I know your group is leading a clinical trial looking at camu camu and kidney cancer, and we're excited to see how that compares to FMT or LBPs, because that might be a potentially scalable alternative. Dr. Sumanta (Monty) Pal: That's awesome. What a terrific overview, and that was less than two minutes. I don't know how you did it. That's terrific. Arielle, this has been such an insightful conversation. I just want to thank you for, again, a terrific article in the ASCO Educational Book. I highly recommend all of our listeners to go there and check it out, and also for sharing all these terrific insights on the podcast today. Dr. Arielle Elkrief: Thank you so much, Monty. Dr. Sumanta (Monty) Pal: And thanks to our listeners, too. If you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Sumanta (Monty) Pal @montypal Dr. Arielle Elkrief Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Sumanta (Monty) Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Arielle Elkrief: Honoraria: AstraZenica, Bristol-Myers Squibb, Merck, EMD Serono Consulting or Advisory Role: Bristol-Myers Squibb Research Funding (Inst.): Kanvas Bioscience, AstraZeneca, Merck Other Relationship: Royal College of Surgeons and Physicians of Canada, Cedar's Cancer Center (Henry R. Shibata Fellowship), Canadian Institutes of Health Research (CIHR)
On episode #87 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 7/31/25 – 8/18/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged ≥50 years (CID) Bacterial Dalbavancin for Treatment of Staphylococcus aureus Bacteremia (JAMA) Propensity-Matched Comparison of Timely vs. Delayed Antibiotic Therapy in Stenotrophomonas maltophilia Pneumoni (OFID) The proportion of Treponema pallidum PCR-positive primary syphilis infections which are seronegative for syphilis (OFID) Cefixime versus benzathine penicillin G for the treatment of early syphilis (Journal of Antimicrobial Chemotherapy) Dalbavancin for Treatment of Staphylococcus aureus Bacteremia (JAMA) Fungal The Last of US Season 2 (YouTube) Parasitic Increasing Length of the Babesia Season in New England in the Climate Change Era (OFID) Ivermectin to Control Malaria (NEJM) Miscellaneous ACIP Recommendations Summary (CDC: Influenza) Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score (JID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.
Are germs truly the villains of human health—or have we misunderstood the body's healing process from the very beginning? In this eye-opening episode of the Know Better | Do Better Podcast, Autumn sits down with Liev Dalton, founder of Beyond Terrain, to dismantle mainstream medical myths and reveal the truth behind the terrain paradigm. From pleomorphism and the flaws of PCR testing to ancestral wisdom and the body's natural detox processes, Liev uncovers why germ theory may be the greatest medical misdirection of our time—and how reclaiming your health starts with honoring your body, not fearing it. If you've ever questioned the medical system, wondered why symptoms keep coming back, or felt drawn to holistic, root-cause healing, this conversation will challenge everything you thought you knew about illness, microbes, and healing.
HIV, superbugs, and standards—oh my! In this episode of Absolute Gene-ius, we explore the frontier of infectious disease research with Dr. Jesús Mingorance, researcher at Hospital Universitario La Paz in Madrid. His research is translational and uses digital PCR, qPCR, sequencing, and more.Dr. Mingorance walks us through his application of ultra-sensitive PCR methods to track HIV-2 viral loads—particularly in challenging cases where standard assays fall short. He shares how digital PCR enabled detection in samples where conventional tests failed, and how it's becoming essential for assay calibration and microbial quantification. He also dives into the endemic challenges of carbapenem-resistant Klebsiella pneumoniae in hospitals, revealing the clinical and epidemiological importance of quantifying pathogen load within the microbiome.In the career corner, Dr. Mingorance recounts his unconventional journey—from humanities student to biologist inspired by a single sentence about DNA. With humor and honesty, he reflects on the patience needed in science, the value of good questions, and the importance of mentoring new scientists. “Biology is beautiful,” he reminds us. We agree.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System.
Dean's Chat hosts, Drs. Jeffrey Jensen and Johanna Richey, welcome Dr. Joseph Coppola to the podcast! Dr. Coppola is a yound practitioner in Massachusetts, practicing in Community Health Centers in Lynn and Peabody. A fantastic discussion on underserved communities, the medical challenges, the creative ways care can be delivered, and the compassion and empathy he has for his patients. Joseph has been in education since 2012, teaching within the Boston Public Health Commission/Boston University School of Medicine. He taught Anatomy, Physiology, and Biology to high school students. His life long passion for teaching is evident. A graduate of the New York College of Podiatric Medicine in 2020, Dr. Coppola did his 3 year residency training in Podiatric Medicine and Surgery at the Metrowest Medical Center in Framingham, MA. We had a chance to talk about our Dean's Chat sponsor, Bako Diagnostics, as Dr. Coppola participated in the Bako Diagnostics Mini-Fellowship in April 2023. We discussed the intensive Dermatopathology rotation that focuses on the principles of Podiatric Dermatology. He learned different biopsy techniques, utilization of instruments with exposure to specialized testing such as ENFD, immunohistochemistry, mass spectrometry, and real time PCR interpretations of complex cases from the lower extremity. Enjoy!
Gut Health Over 40: Tiny Health's Microbiome, Longevity, and ResilienceClick On My Website Below To Schedule A Free 15 Min Zoom Call:www.Over40FitnessHacks.comOver 40 Fitness Hacks SKOOL Group!Get Your Whoop4.0 Here!Cheryl Sew Hoy - CEO of "Tiny Health"www.TinyHealth.comSocials: @Tiny.HeatlhPodcast Summary: Brad Williams (Over 40 Fitness Hacks) welcomed Cheryl, founder of Tiny Health, after first learning about her company through Crowd Health. Brad shared his personal journey with gut testing, food allergies, and how microbiome awareness changed his approach to health. He also mentioned his recent Tiny Health score of 82/100, which outperformed his family's results.Cheryl (age 42, mom of three) founded Tiny Health after her first child, born via C-section, developed eczema and food allergies linked to disrupted microbiome colonization.Determined to prevent the same issues, she researched microbiome science and saw improved outcomes with her next two children (both vaginal births, no allergies).Tiny Health began with a focus on baby gut health but was always designed to expand into longevity and adult health, supporting people through all stages of life.Today, Tiny Health powers gut testing not only for families but also for longevity clinics, health assessment companies, and even the Mayo Clinic.Microbiome Importance: 80% of the immune system is housed in the gut. Early life gut balance impacts long-term immune strength, allergy risk, metabolic health, and autoimmune conditions.Technology Advantage: Traditional stool tests (PCR) only detect targeted pathogens, while Tiny Health uses metagenomic sequencing to capture a complete, functional view of the microbiome, including beneficial bacteria and pathways.Scoring & Metrics: Results include overall gut scores, resilience scores, antibiotic resistance, and insights into digestion, immune function, and hormone regulation.Supplements vs. Food:Supplements can help correct imbalances short-term, but lasting gut health requires prebiotic fibers and diverse whole foods.Fermented foods and polyphenol-rich foods (like berries) boost diversity and resilience.Leaky Gut Explained: The gut lining acts like a castle wall; without enough butyrate (produced by fiber-digesting bacteria), food particles and pathogens can cross, triggering immune responses and food sensitivities.Resilience & Recovery: Antibiotics, infections, or travel (“Bali belly”) can disrupt the microbiome for months or longer. Retesting 4–6 weeks after such events helps measure recovery.Aging Microbiome: After 40, resilience decreases, making gut testing and diet/lifestyle adjustments more important.Red Meat & Alcohol: Red meat isn't inherently bad, but must be balanced with fiber to prevent protein fermentation issues. Alcohol negatively impacts gut health and sleep, but moderation and timing can help reduce effects.If you're interested in online personal training or being a guest on my podcast, "Over 40 Fitness Hacks," you can reach me at brad@over40fitnesshacks.com or visit my website at:www.Over40FitnessHacks.comAdditionally, check out my Yelp reviews for my local business, Evolve Gym in Huntington Beach, at https://bit.ly/3GCKRzV
In this episode of For Pet's Sake, Mark from Bella+Duke talks to Charlotte, head of clinical administration at Wormcount, about parasite prevention, faecal testing, and why targeted deworming is better than blanket treatment. Learn how to spot signs of worm infestations, why chemical dewormers don't provide long-term protection, and how PCR testing is revolutionizing parasite detection for pets. Charlotte also discusses zoonotic risks, the environmental impact of over-deworming, and the importance of routine testing for dogs of different lifestyles. If you're a pet owner looking to safeguard your dog's health, prevent resistant parasites, and understand modern parasite management, this episode is packed with essential insights.
Pop Culture Revolution has moved to a new home! Absolute DMV Podcast Network! DJ Boss Player and Mori christened the new season! DJ Boss Player's wife brought cake and champagne to celebrate! They caught up on all the hot topics they missed since the last episode in May! And they took a "Deep Dive" into the topic of capitalism in the USA! And now we're going to have video content in addition to the audio distribution! Look out for it in the coming days! We're back with a new swag and better than EVER! Join the Revolution!
If you've been trying to conceive with low AMH, high FSH, diminished ovarian reserve (DOR), or poor egg quality and nothing seems to be working… or if you've experienced failed IVF cycles or unexplained pregnancy loss - this episode is for you. We're diving into one of the most overlooked infections that could be silently impacting your fertility: Ureaplasma. This commonly missed microbe can compromise egg quality, disrupt implantation, and contribute to early miscarriage, even when labs appear “normal.” Whether you're TTC naturally or preparing for an IVF or FET cycle, you'll learn: How Ureaplasma affects egg and embryo quality, implantation, and ovarian reserve Why this infection is often missed on standard fertility workups The importance of partner testing and treating both partners When and how to test for Ureaplasma The functional fertility approach we use at Fab Fertile to rebalance the vaginal and seminal microbiome for optimal conception If you've done “all the things” and still aren't seeing results, this episode may reveal a missing piece of your fertility puzzle. This episode is for you if: You're struggling to conceive naturally despite doing “all the right things.” You've had failed IVF transfers, poor egg quality, or low ovarian reserve without clear answers. You've experienced recurrent infections or unexplained pregnancy losses. 5 Key Points: Why Ureaplasma and Mycoplasma are often missed in standard fertility testing and why they matter for egg quality, implantation and pregnancy maintenance. How Ureaplasma can contribute to low AMH, high FSH, and diminished ovarian reserve by increasing inflammation in the reproductive tract and altering the vaginal microbiome. The link between Ureaplasma and recurrent miscarriage, failed IVF, and abnormal embryos, even when other tests are “normal”. The functional fertility approach to addressing Ureaplasma with targeted antimicrobials, vaginal microbiome restoration, and gut health support for natural and assisted conception. --- TIMESTAMPS [00:00:00] Intro: Ureaplasma's hidden role in fertility struggles, natural conception, failed IVF, low AMH, DOR, poor egg quality, and unexplained pregnancy loss. [00:01:00] Who this episode is for: Fertility challenges including low AMH, high FSH, DOR, RPL, recurrent infections, and unexplained infertility. [00:02:00] What is ureaplasma? Impact on vaginal and seminal microbiome, egg and sperm quality, inflammation, and implantation failure. [00:03:00] Who should get tested? Those with unexplained infertility, recurrent pregnancy loss, persistent infections, elevated CRP/ANA, poor IVF outcomes, or partner infection history. [00:04:00] Why microbiome testing matters: Gut, vaginal, and seminal microbiome panels uncover hidden infections missed by conventional testing. [00:05:00] Key red flags: Multiple failed IVF transfers, RPL after heartbeat confirmation, chronic vaginal/urinary symptoms, and abnormal semen analysis. [00:06:00] Testing methods: Functional medicine/nutrition, PCR, and microbiome panels (e.g., Juno Bio) versus limited conventional testing. [00:07:00] Supporting Fertility Success: Using biofilm disruptors and restoring balance in gut and vaginal microbiomes to improve egg quality and IVF outcomes. --- How to Get Started With Functional Fertility Support Book your call here to get your personalized plan and options to help improve pregnancy success either naturally or with IVF treatment. Check out our Fab Fertile functional fertility program here and learn how to improve AMH levels naturally. We work with couples that have low AMH, high FSH, diminished ovarian reserve, premature ovarian insufficiency, and recurrent pregnancy loss. --- RESOURCES Before Your IVF Transfer, Test This First: https://fabfertile.com/blogs/podcasts/before-your-ivf-transfer-test-this-first?_pos=4&_sid=c1bed4027&_ss=r IVF Prep with Low AMH: Boosting Your Chances for Success: https://fabfertile.com/blogs/podcasts/ivf-prep-with-low-amh-boosting-your-chances-for-success-1?_pos=1&_sid=2685fd59c&_ss=r Causes of Miscarriage Before 12 Weeks: What Most Doctors Miss: https://fabfertile.com/blogs/podcasts/causes-of-miscarriage-before-12-weeks-what-most-doctors-miss What You Need To Know About Chronic Infections And Infertility: https://fabfertile.com/blogs/podcasts/what-you-need-to-know-about-chronic-infections-and-infertility?_pos=2&_sid=1142152ce&_ss=r Our favorite fertility tracker Inito (use code FABFERTILE15 to save 15) Studies Today's study looks at Ureaplasma urealyticum, a common genital tract infection, and how it affects IVF. Researchers found it didn't affect fertilization or embryo quality but was linked to lower pregnancy rates after embryo transfer. The culprit? Infection in the endometrial lining which can disrupt implantation. So even if embryos look good Ureaplasma can still sabotage IVF success. https://academic.oup.com/humrep/article-abstract/6/5/727/609246?redirectedFrom=fulltext This study looked at whether Ureaplasma urealyticum in men's semen affects IVF. The results? Fertilization and pregnancy rates were the same for infected and uninfected men. But here's the thing, miscarriage rates were much higher in couples where the male partner had the infection. So Ureaplasma might not stop you from getting pregnant but it can increase the risk of losing the pregnancy. https://www.fertstert.org/article/S0015-0282(98)00472-5/fulltext Ultimate Guide to Getting Pregnant This Year If You Have Low AMH/High FSH ---
FREEDOM - HEALTH - HAPPINESSThis podcast is highly addictive and seriously good for your health.SUPPORT DOC MALIK To make sure you don't miss any episodes, have access to bonus content, back catalogue, and monthly Live Streams, please subscribe to either:The paid Spotify subscription here: https://creators.spotify.com/pod/show/docmalik/subscribe The paid Substack subscription here: https://docmalik.substack.com/subscribeThank you to all the new subscribers for your lovely messages and reviews! And a big thanks to my existing subscribers for sticking with me and supporting the show! ABOUT THIS CONVERSATION: Attorney Tom Renz and I dig into the lies, fear tactics, and deep state manipulation that defined the COVID plandemic. From rigged PCR testing to the PREP Act's corporate immunity, we expose the fraud, call out weak leadership, and talk about the personal cost of fighting for truth and freedom. This is about courage, accountability, and the battle for our children's future.See my substack for more information.Much love, as always.Doc MalikLinksWebsite https://tomrenz.com/IMPORTANT INFORMATIONCONSULTATION SERVICEIn a world of rushed 7-minute consultations and endless referrals, I offer you something rare: time, context, and clear guidance.As your health advocate, I can help you:Understand your diagnosis and decode medical jargonDecide who to see: GP, specialist, osteopath, physio, accupuntcurist, homeopath etc?Break down treatment plans in plain, easy to understand non jargon EnglishPrepare for surgery, understand your risks, obtain true informed consent, and optimise yourself pre-op Recover from surgery, advise you how to heal faster and quicker and minimise post-op complicationsManage chronic illness with lifestyle, mindset, and dietary changesExplore holistic options that complement conventional careImplement lifestyle changes like fasting, stress reduction, or movementAsk better questions, and get real answersGet an unbiased second opinionReady to Take Control?If you're navigating a health concern, preparing for a big decision, or simply want to feel more confident in your path forward, I'd love to support you.Book here https://docmalik.com/consultations/ Because it's your body, your life, and your future. Let's make sure you're informed and heard.WaterpureI distill all my water for drinking, washing fruit and vegetables, and cooking. If you knew what was in tap water, so would you!https://waterpure.co.uk/docmalik BUY HERE TODAYHunter & Gather FoodsSeed oils are inflammatory, toxic and nasty; eliminate them from your diet immediately. Check out the products from this great companyhttps://hunterandgatherfoods.com/?ref=DOCHG BUY HERE TODAYUse DOCHG to get 10% OFF your purchase with Hunter & Gather Foods.IMPORTANT NOTICEIf you value my podcasts, please support the show so that I can continue to speak up by choosing one or both of the following options - Buy me a coffee If you want to make a one-off donation.Doc Malik Merch Store Check out my amazing freedom merch
Nesse episódio, o Dr. Vinícius Zofoli, intensivista e editor-chefe de terapia intensiva do portal Afya, discute como utilizar a ecocardiografia no contexto da PCR. Aperte o play e ouça agora! Confira esse e outros posts no Portal Afya e siga nossas redes sociais!FacebookInstagramLinkedinTwitter
Ready to get real about breast augmentation? In this episode, we're diving deep into the world of cosmetic surgery with a no-holds-barred conversation you won't want to miss! Today, Dr. Robert Whitfield speaks with a patient, Kathy Dixon, who's here to share her personal journey. Kathy opens up about how her cultural background shaped her decisions, her struggles with breast implant illness, and what led her to choose explant surgery. Tune in to hear so much more! Kathy's Business, Oh Yes Communications (https://www.ohyescommunications.com/author/kathy/) Show Highlights: Kathy's Cultural Influences & Decision for Augmentation (00:02:45) *Kathy discusses her Colombian heritage, body image, and initial decision to pursue breast augmentation. *Cultural Trends in Plastic Surgery (00:08:21) South American vs. U.S. beauty standards, Brazilian butt lifts, and safety concerns. Fat Transfer Misconceptions & Technical Details (00:09:11) Differences between fat transfer to buttocks, face, and breasts, and addresses misconceptions Kathy's Surgical Journey & Onset of Symptoms (00:16:29) *Kathy recounts her initial surgery, complications, and the gradual onset of physical and emotional symptoms. *Medical Dismissal & Search for Answers (00:18:36) Being dismissed by doctors, pursuing hormone testing, and discovering breast implant illness Testing, Mold, and Mycotoxins (00:20:34) High mold count; surgeon discusses PCR testing, bacterial contamination, and importance of thorough pathology Challenges in Women's Health & Medical Gaslighting (00:28:00) Lack of support for women, medical gaslighting, and inappropriate reliance on birth control for hormone issues Mold, Detoxification, and Environmental Factors (00:33:37) *Environmental and dietary sources of mold, detox challenges, and lifestyle changes *Post-Surgery Recovery & Lifestyle Adjustments (00:44:11) *Recovery goals, physical therapy, emotional healing, and the importance of support systems *Support Systems & Patient Experience (00:48:25) Importance of family support, patient education, and realistic expectations for recovery Links and Resources Let's Connect Podcast: https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554 Spotify: https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667 TikTok: https://www.tiktok.com/@drrobertwhitfield?t=8oQyjO25X5i&r=1 IG: https://www.instagram.com/breastimplantillnessexpert/ FB: https://www.facebook.com/DrRobertWhitfield Linkedin: https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/ X: https://x.com/rob_whitfieldmd Read this article - https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness Shop: https://drrobssolutions.com SHARP: https://www.harp.health NVISN Labs - https://nvisnlabs.com/ Get access to Dr. Rob's Favorite Products below: Danger Coffee - Use our link for mold free coffee - https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg JASPR Air Purifier - Use code DRROB for the Jaspr Air Purifier - https://jaspr.co/ Echo Water - Get high quality water with our code DRROB10 - https://echowater.com/ BallancerPro - Use code DRROBVIP for the world's leader in lymphatic drainage technology - https://ballancerpro.com Ultrahuman - Use code WHITFIELD10 for the most accurate wearable - https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield
Maryam Heinen is the author of Operation George Floyd. Get the book or documentary at www.maryamhenein.comLow Value Mail is a live call-in show with some of the most interesting guests the internet has to offer.Every Monday night at 7pm ETSupport The Show:
In this follow-up conversation with Raw Farm's CEO & Founder Mark McAfee, we explore the nuanced differences between raw milk and UV pasteurization technology. Mark shares his expert perspective on UV treatment as a middle ground between raw milk and traditional heat pasteurization, explaining why it preserves some bioactives while eliminating the beneficial bacterial diversity that makes raw milk unique.We dive into the technical aspects of milk safety, including Raw Farm's advanced PCR testing protocols that provide daily pathogen screening, and discuss the practical challenges of scaling raw milk production. Mark also shares his guide on how to source clean raw milk from your local farm. About Mark McAfeeMark McAfee founded the Raw Milk Institute (RAWMI) in 2011 to assure that farmers had a resource to assist them in producing very low risk raw milk for their consumers. Mark is passionate about “grass to glass” risk reduction management on the farm, and he believes that raw milk cannot emerge as a trusted food unless it is very low risk. He is certified in HACCP management from Chapman University and has developed and implemented award winning Food Safety Plans including Raw Milk Risk Analysis & Management Plans (“RAMP”).Links & ResourcesIntro to raw milk episode with Mark McAfee and Max KaneBob Comstock episode on UV pasteurization technologyGuide: How to Find a Good Raw Milk FarmerRaw milk finder: https://www.realmilk.com/raw-milk-finder/Raw Farm website: https://rawfarm.comCornell University 2021 study on bioactives in milkDiscounts Get 10% off delicious local farm-fresh food delivered to your door with my link for FarmMatch: https://farmmatch.com/jane Get 15% off high-quality Italian olive oil with code FARMTOFUTURE: https://shop.vignolifood.com/FARMTOFUTURE Get 40% the CircleDNA's Premium DNA test with code JANEZHANG: https://circledna.com/premium Connect with Jane Z. Instagram: @farm.to.future Email: jane@farmtofuture.co Website: farmtofuture.co
In this episode of The ICHE Podcast, we take a deep dive into the evolving role of plasma cell-free DNA (cfDNA) metagenomic next-generation sequencing (mNGS) in the diagnosis of infectious diseases. Hosted by experts from UCLA Health, this discussion breaks down what cfDNA mNGS is, how it differs from more traditional pathogen detection tools like PCR, and where it fits in the diagnostic landscape. Dr. Ishminder Kaur, Dr. Daniel Uslan, and Dr. Shangxin Yang join the episode to explore the clinical utility, benefits, and pitfalls of this rapidly emerging diagnostic modality. The group reviews several individual studies, highlighting how they approached their research questions, key findings, and the implications for patient care and antimicrobial stewardship. The conversation also addresses challenges such as interpreting complex results, cost considerations, and potential overuse. Whether you're a clinician, laboratorian, or infection preventionist, this episode provides critical insights into when and how cfDNA mNGS may enhance your diagnostic toolkit—and when it might not. Each guest closes with a practical takeaway: concrete advice for healthcare professionals who are considering incorporating cfDNA testing into their own clinical or infection control practice.
Can you detect Alzheimer's with a spit sample? That's the question driving Arianna Arbona's exciting research at Universidad Pablo de Olavide in Sevilla, Spain. In this episode of Absolute Gene-ius, she shares how she's isolating microvesicles from saliva and blood to identify early biomarkers for neurodegenerative diseases like Alzheimer's—an effort that could one day lead to minimally invasive diagnostic tools.Arianna describes the scientific and technical hurdles she's overcoming, from low vesicle concentrations to validating the brain-specific origin of those vesicles. She also reflects on her previous lupus research, where digital PCR enabled detection of faint mRNA signatures that qPCR missed—making it an essential tool for rare target quantification. Her future plans include integrating immuno-PCR and multiplex assays for more sensitive and multi-marker detection in Alzheimer's and beyond.In the career corner, Arianna recounts her journey from the Canary Islands to Helsinki to Sevilla, balancing passion, mentorship, and a healthy sense of humor. She talks about working through uncertainty after her master's degree, the mentors who kept her smiling, and how an early accidents taught her resilience. Her message to aspiring scientists: follow your curiosity and don't be afraid to change direction.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System.
Jerneja Tomsic is a rebellious, outspoken gal (thank goodness) who carries a PhD in Molecular Biology. Being from Slovenia (as is Melania Trump), she knows about socialism... down to the untruths of science paradigms because she is in that world, is now awake and researches. From the lies of PCR tests being effective in diagnosing Co*v*d down to the truth of DNA/double helix, cancer, mammograms, viruses and bacteria.For the "Just Be Practice," Jerneja highlights how fear is the real virus.References for the show:https://viroliegy.comConversation on breast health:https://odysee.com/@Dawn-Lester:3/Conversation-with-Robyn---Jerneja:eLinks to Jerneja:Her Rumble channel: https://rumble.com/user/Jerneja18Chat with Kevin Corbett on PCR tests for The End of COVID project:https://odysee.com/@TheEndOfCovid:3/20230706-TEOC-TEOC-SESSION-The-PCR-Tests--Dr--Jerneja-Tomsic--Dr--Kevin-Corbett-MULTICAM-CUT-2-mov-by-NA:bThe Scientific Method:https://rumble.com/v59dcal-mwk-science-1-the-scientific-method-jerneja-tomsic.htmlPeer Review:https://rumble.com/v5b8wcd-mwk-science-2-peer-review-jerneja-tomsic.html*Host Eden Koz is a soul realignment specialist utilizing such gifts as psychological empathy, intuition, psychic ability, mediumship, meditation, mindset shift, Reiki, dimensional and galactic healing, to name a few. She can also perform a spiritual Co#id Vac+ Healing as well as remote & face-to-face sessions with individuals and groups. Contact info for Eden Koz / Just Be®, LLC:Website: EdenJustBe.com Socials: Insta, FB, FB (Just Be), LinkedIn Just Be~Spiritual BOOM Podcast can be found on the audio directories: Apple Podcasts, Spotify, Amazon Music, Stitcher, iHeart Radio, TuneIn+Alexa, ...
Stool testing technology has advanced rapidly in recent years, with newer methods like PCR and whole-genome sequencing offering faster and more precise insights into the gut microbiome. These innovations have transformed how clinicians approach gut health, allowing for more targeted interventions. However, older technologies—such as microscopy, culture, and enzyme-based assays—still play a valuable role. These methods provide functional insights that molecular tools may miss, such as direct observation of parasites or assessment of digestive markers. The most comprehensive labs recognize that no single method gives the full picture. Instead, combining the strengths of both modern and traditional techniques ensures more accurate, clinically meaningful results. In this episode, we dive into the pros and cons of different laboratory methodologies used in stool testing—from culture and microscopy to PCR and advanced sequencing. We break down how these choices impact accuracy, sensitivity, and clinical usefulness. You'll also learn why Genova Diagnostics stands out for its integrative, evidence-based approach, combining multiple testing methods to deliver the most comprehensive and clinically actionable results available. Today on The Lab Report: 4:00 Technology grows quickly, and the microbiome is complex 7:30 Microbiology culture 12:40 PCR – very precise if done correctly! 17:00 Interpreting the laundry list 20:10 Remember the microscope? 23:30 Whole-genome (shotgun) sequencing pros/cons 27:15 Genova does it all – and well Additional Resources: GI Effects Stool Profile Microbiomix Subscribe, Rate, & Review The Lab Report Thanks for tuning in to this week’s episode of The Lab Report, presented by Genova Diagnostics, with your hosts Michael Chapman and Patti Devers. If you enjoyed this episode, please hit the subscribe button and give us a rating or leave a review. Don’t forget to visit our website, like us on Facebook, follow us on Twitter, Instagram, and LinkedIn. Email Patti and Michael with your most interesting and pressing questions on functional medicine: podcast@gdx.net. And, be sure to share your favorite Lab Report episodes with your friends and colleagues on social media to help others learn more about Genova and all things related to functional medicine and specialty lab testing. To find a qualified healthcare provider to connect you with Genova testing, or to access select products directly yourself, visit Genova Connect. Disclaimer: The content and information shared in The Lab Report is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in The Lab Report represent the opinions and views of Michael Chapman and Patti Devers and their guests.See omnystudio.com/listener for privacy information.
01:00:45 – 01:07:03UN-Backed One-World Climate Religion and Indoctrination in SchoolsCoverage details a global initiative to unite religions under environmentalism, replacing Judeo-Christian morality with “common values” aligned to Agenda 2030. Education systems, the Vatican, and the UN are identified as key actors in promoting this shift, with critiques of figures like Pope Francis and references to occultist influences on global spirituality. 01:21:14 – 01:29:28Homeschooling Crackdown and Christian Persecution in ChinaA deep dive into illegal homeschooling under China's communist regime, highlighting a pastor's defiance in educating his children biblically and the risks parents face, including imprisonment and loss of educational access. The narrative contrasts this with U.S. leniency and warns about potential future parallels. 02:07:33 – 02:14:5622 States Support Lawsuit Against School Over Gender Transition Without Parental ConsentA New Jersey father sues after his daughter is socially transitioned by school staff without his knowledge. The case raises questions about state overreach, parental rights, and the ideology embedded in public education, prompting a national coalition of states to intervene. 02:54:24 – 02:55:27Metadata Comparison to Obama's Birth Certificate Sparks Broader DistrustAnalysis of the Epstein footage metadata triggers comparisons to the Obama birth certificate controversy, where layered files were also detected. Critics suggest this pattern of digital tampering exposes a long-standing culture of government deceit and misuse of Adobe tools to fabricate documents. 03:01:38 – 03:04:21Trump Reverses on Epstein Files, Blames Political EnemiesTrump dismisses the Epstein files as fabricated by Democrats, despite having campaigned on releasing them. The narrative is described as a “mutual destruction” scenario implicating both parties, and his sudden shift is portrayed as preemptive damage control amid growing MAGA backlash. 03:06:51 – 03:08:09Epstein-Mossad Theory Reemerges Amid Trump Loyalty CriticismA claim resurfaces that Epstein worked for Israeli intelligence and acquired blackmail material on Trump. The connection is tied to Israeli elites like Ehud Barak and Les Wexner, with allegations that these ties explain Trump's consistent alignment with Israeli interests. 03:39:42 – 03:42:14Charges Dropped Against COVID Vaccine Skeptic Dr. Kirk MooreAttorney General Pam Bondi orders charges dismissed against Dr. Kirk Moore, who was accused of issuing fake COVID vaccine cards and destroying doses. The move is portrayed as a political concession to the MAGA base, with criticism of the government's original crackdown and praise for Moore's resistance to mandates. 03:56:19 – 03:57:09Push to Remove Vaccine Liability Protections and Enable LawsuitsAdvocates urge lawmakers to revoke immunity protections for vaccine makers and reclassify mRNA injections as gene-altering. The segment calls for retroactive lawsuits, arguing that only direct legal consequences will halt corporate harm. 03:57:47 – 03:58:32COVID Measures Blamed for More Harm Than Virus ItselfClaims are made that the "cure"—vaccines, ventilators, and Remdesivir—caused more deaths than COVID. The PCR test is mocked as unreliable, and the segment portrays pandemic policy as a coordinated scam by the healthcare system. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.
01:00:45 – 01:07:03UN-Backed One-World Climate Religion and Indoctrination in SchoolsCoverage details a global initiative to unite religions under environmentalism, replacing Judeo-Christian morality with “common values” aligned to Agenda 2030. Education systems, the Vatican, and the UN are identified as key actors in promoting this shift, with critiques of figures like Pope Francis and references to occultist influences on global spirituality. 01:21:14 – 01:29:28Homeschooling Crackdown and Christian Persecution in ChinaA deep dive into illegal homeschooling under China's communist regime, highlighting a pastor's defiance in educating his children biblically and the risks parents face, including imprisonment and loss of educational access. The narrative contrasts this with U.S. leniency and warns about potential future parallels. 02:07:33 – 02:14:5622 States Support Lawsuit Against School Over Gender Transition Without Parental ConsentA New Jersey father sues after his daughter is socially transitioned by school staff without his knowledge. The case raises questions about state overreach, parental rights, and the ideology embedded in public education, prompting a national coalition of states to intervene. 02:54:24 – 02:55:27Metadata Comparison to Obama's Birth Certificate Sparks Broader DistrustAnalysis of the Epstein footage metadata triggers comparisons to the Obama birth certificate controversy, where layered files were also detected. Critics suggest this pattern of digital tampering exposes a long-standing culture of government deceit and misuse of Adobe tools to fabricate documents. 03:01:38 – 03:04:21Trump Reverses on Epstein Files, Blames Political EnemiesTrump dismisses the Epstein files as fabricated by Democrats, despite having campaigned on releasing them. The narrative is described as a “mutual destruction” scenario implicating both parties, and his sudden shift is portrayed as preemptive damage control amid growing MAGA backlash. 03:06:51 – 03:08:09Epstein-Mossad Theory Reemerges Amid Trump Loyalty CriticismA claim resurfaces that Epstein worked for Israeli intelligence and acquired blackmail material on Trump. The connection is tied to Israeli elites like Ehud Barak and Les Wexner, with allegations that these ties explain Trump's consistent alignment with Israeli interests. 03:39:42 – 03:42:14Charges Dropped Against COVID Vaccine Skeptic Dr. Kirk MooreAttorney General Pam Bondi orders charges dismissed against Dr. Kirk Moore, who was accused of issuing fake COVID vaccine cards and destroying doses. The move is portrayed as a political concession to the MAGA base, with criticism of the government's original crackdown and praise for Moore's resistance to mandates. 03:56:19 – 03:57:09Push to Remove Vaccine Liability Protections and Enable LawsuitsAdvocates urge lawmakers to revoke immunity protections for vaccine makers and reclassify mRNA injections as gene-altering. The segment calls for retroactive lawsuits, arguing that only direct legal consequences will halt corporate harm. 03:57:47 – 03:58:32COVID Measures Blamed for More Harm Than Virus ItselfClaims are made that the "cure"—vaccines, ventilators, and Remdesivir—caused more deaths than COVID. The PCR test is mocked as unreliable, and the segment portrays pandemic policy as a coordinated scam by the healthcare system. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.
Having met at the UC Davis Wine Executive Program, Kia Behnia, CEO, and Mason Earles, CTO, founded Scout to replicate the best sensor in the vineyard, “the farmer's eye.” Leveraging off-the-shelf hardware, Scout uses AI to process images taken from a tractor to automate vineyard mapping, vine counting, yield forecasting, virus identification, and more. From managing vineyard assets to implementing precision agriculture to improve quality, Scout is harnessing the power of AI to optimize vineyard management.Detailed Show Notes: Mason's background - UC Davis Professor, Apple, AI & agricultureKia's background for Scout - owns the Neotempo wine brand, worked at Splunk, the “data for everything” companyThe official company name is Agricultural Scout, dba Scout, the website is agscout.ai, so it can be called any of those namesFounded in 2022, initially more hardware-based, but pivoted to an intelligence company using off-the-shelf hardwareThe goal is to “replicate the farmer's eye” with an AI-based solution using cameras, tractors, and Scout cloud and mobile app (which can be used offline); the brain is centered around a phoneUS only today (~50-100 clients, 300 blocks, 2M vines, processed 56M photos), going international in 20264 main use cases currently: Automate vine count, inventory, and mapping of vines - 4x faster than people could doEstimate crop performance - both vigor and fruitYield forecasting - can use every step in the growing season to forecast yield with historical performance and weather forecastsHealth performance and vine mapping - leveraging AI for virus detection3 types of clientsEstate wineriesVineyard management companies (“VMC”)Real estate investors or owners to track vineyardsBenefits include: $400-1,200 savings/acreProductivity gains through managing more acres with fewer people, identifying low-performing vines, and the program tells farmers where to sampleRemote monitoring of faraway vineyardsEarly season yield forecastingDisease management - virus can cause $170k/acre damage over 3-5 years, costs $40/PCR test, the goal is to keep virus 50 acresNeighborhood and AVA discountsStarter - 2 scan package (for inventory and virus)Professional - 6 scan packageTypical customer starts w/ 2 and upgrades to 6Monarch promotion, customers get 1 free scanUp front hardware costs ~$3,000New product in beta in July 2025 - ChatGPT Scout for vineyardsMarketing mostly through word of mouth, industry trade shows, and webinars have been effective, as has partnership with Monarch (already tech enthusiasts)Barriers to purchase are often due to farming budgets built around labor Hosted on Acast. See acast.com/privacy for more information.
© 2020-2025 Ivy Podcast Discovery LLC
